ACB - Aurora Cannabis Inc.

NYSE - NYSE Delayed Price. Currency in USD
-1.26 (-8.21%)
At close: 4:00PM EDT

14.25 +0.17 (1.21%)
After hours: 5:02PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close15.34
Bid14.20 x 800
Ask14.04 x 1800
Day's Range13.78 - 14.66
52 Week Range5.30 - 97.92
Avg. Volume9,661,437
Market Cap1.557B
Beta (5Y Monthly)1.40
PE Ratio (TTM)65.19
EPS (TTM)0.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Why Aurora Cannabis Stock Dropped 10% This Morning
      Motley Fool

      Why Aurora Cannabis Stock Dropped 10% This Morning

      Canadian cannabis kingpin Aurora Cannabis (NYSE: ACB) closed its acquisition of Massachusetts-based cannabidiol (CBD) maker Reliva LLC last night in a $40 million deal (or more than twice that, if Reliva hits certain financial milestones over the next couple of years). Aurora Cannabis stock plunged more than 10% as soon as trading resumed this morning and hasn't gained back much since -- down 8.5% as of 12:15 p.m. EDT. Aurora interim CEO Michael Singer says the merger will "create a market leading international cannabinoid platform that we believe can deliver robust revenue and profitable growth."

    • Benzinga

      Aurora Cannabis: Price Over Earnings Insights

      Right now, Aurora Cannabis Inc. (NYSE: ACB) share price is at $13.97, after a 9.11% decrease. Over the past month, the stock spiked by 65.22%, but over the past year, it actually decreased by 83.78%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.The stock is currently higher from its 52 week low by 2228.30%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with specialty & generic drug manufacturers stocks, and capitalize on the lower share price observed over the year.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Aurora Cannabis Inc. has a lower P/E than the aggregate P/E of 34.38 of the specialty & generic drug manufacturers industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * Morning Market Stats in 5 Minutes * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga does not provide investment advice. All rights reserved.

    • Can Aurora Cannabis Recover in 2020?
      Motley Fool

      Can Aurora Cannabis Recover in 2020?

      Well, here's a twist: The COVID-19 pandemic might have dragged down most sectors, but it is lifting up marijuana stocks for sure. Edmonton, Alberta-based Aurora Cannabis (NYSE: ACB) saw strong demand after Canada legalized recreational marijuana in 2018. External factors including black-market sales and a slow rollout of stores post-legalization made it harder for the company to make a profit; ultimately, investors lost trust, and the stock kept sinking below $1 -- to the point that it was at risk of being delisted from the New York Stock Exchange.

    • Aurora Cannabis Acquisition of Reliva Closes
      Motley Fool

      Aurora Cannabis Acquisition of Reliva Closes

      Aurora Cannabis' (NYSE: ACB) latest asset buy is in the books. The company announced on Thursday that its purchase of Reliva, a maker of hemp-derived cannabidiol (CBD) products, has closed. The news comes just over a week after Aurora divulged that it and Reliva had agreed to the acquisition.

    • Why Aurora's Expansion Into the U.S. Market Really Isn't All That Exciting
      Motley Fool

      Why Aurora's Expansion Into the U.S. Market Really Isn't All That Exciting

      In recent weeks, Aurora Cannabis (NYSE: ACB) stock has seen new life. It all started with the company releasing its third-quarter 2020 results on May 14, which showed 18% revenue growth from the prior period. Then, on May 20, the cannabis producer also announced it was acquiring Reliva, a cannabidiol (CBD) brand that would allow it to penetrate the U.S. market.

    • Aurora Cannabis Completes Acquisition of Reliva LLC
      PR Newswire

      Aurora Cannabis Completes Acquisition of Reliva LLC

      Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously announced acquisition of Reliva, LLC ("Reliva") a leader in the sale of hemp-derived CBD products in the United States for approximately US$40 million of Aurora common shares. The transaction also includes a potential earn-out of up to a maximum of US$45 million payable at Aurora's option in shares or cash contingent upon Reliva achieving certain financial targets over the next two years.

    • COVID-19's Surprising Impact on Cannabis Sales
      Motley Fool

      COVID-19's Surprising Impact on Cannabis Sales

      Though marijuana sales have been blazing-hot during the coronavirus pandemic, don't get too high on the monthly sales figures.

    • Don't Believe Aurora Cannabis' Profitability Spin
      Motley Fool

      Don't Believe Aurora Cannabis' Profitability Spin

      When the Canadian cannabis producer uses the word "profitable," it doesn't really mean profitable.

    • Weekly Cannabis Stock News: Aurora Cannabis Gets Back in the Acquisition Game
      Motley Fool

      Weekly Cannabis Stock News: Aurora Cannabis Gets Back in the Acquisition Game

      Last week's big cannabis company news was a throwback to the good old days of 2018 or so, with Aurora Cannabis (NYSE: ACB) signing on the dotted line for a buyout. Canada-based Aurora is reaching across the border for that acquisition. It announced it has agreed to buy U.S. hemp-derived cannabidiol (CBD) products maker Reliva in a deal for roughly $40 million in Aurora common stock, plus up to $45 million over the next two years in cash, stock, or a combination of the two if Reliva meets specific financial goals.

    • Aphria, Aurora Among Top Performers As Canadian Cannabis Sales Spike

      Aphria, Aurora Among Top Performers As Canadian Cannabis Sales Spike

      Canada's recreation cannabis sales grew by 19% in March to reach CA$181.1 million ($131.5 million), ahead of most U.S. states, according to Cantor Fitzgerald.Analyst Pablo Zuanic said that Canada's March sales data was significantly ahead of Cantor's mid-single digit estimate, partly due to pantry loading, but also on account of continued Cannabis 2.0 rollouts.Ratings And Price Targets Cantor analyst Pablo Zuanic maintained the following ratings and price targets on cannabis stocks:Overweight * Aurora Cannabis Inc. (NYSE: ACB) with a CA$27 price target. * Aphria Inc. (NYSE: APHA) with a CA$9.55 price target. * OrganiGram Holdings Inc (NASDAQ: OGI) with a price target of CA$5.60. Neutral * Canopy Growth Corp (NYSE: CGC) with a price target of CA$25. * Tilray Inc (NASDAQ: TLRY) with a price target of $8. Underweight * Hexo Corp (NYSE: HEXO) with a price target of CA$0.72.Cantor's Cannabis Takeaways Comparing Canada's 17th month of recreational cannabis sales with Colorado's figures indicates that the country's market may grow to CA$14 billion by the end of 2024, Zuanic said in the industry note.So far, the best performers in the first quarter are Aphria, with 53% sales growth, and Aurora Cannabis and Tilray, with sales growth in the mid-20% range, the analyst said.Canopy Growth is scheduled to report its March quarter results Friday.Zuanic named Aphria and Aurora Cannabis as top picks.Related Links: Canopy Growth Set To Become Cannabis Sector Leader, Says BofAThe Week In Cannabis: A Great Week For Stocks Driven By Confusion, Aurora's Rally, New Advisors To BenzingaCourtesy photo * Analista: Aphria y Aurora Cannabis Posicionados para Liderar Ventas en CanadaLatest Ratings for APHA DateFirmActionFromTo May 2020Cantor FitzgeraldMaintainsOverweight May 2020Cantor FitzgeraldMaintainsOverweight Apr 2020CIBCMaintainsNeutral View More Analyst Ratings for APHA View the Latest Analyst Ratings See more from Benzinga * Cantor Fitzgerald Says Aurora Cannabis Sell-Off Creates Entry Point * Monthly Canadian Cannabis Sales Increased Ahead Of Coronavirus Pandemic(C) 2020 Benzinga does not provide investment advice. All rights reserved.

    • Why Aurora Cannabis (ACB) Stock Looks Attractive

      Why Aurora Cannabis (ACB) Stock Looks Attractive

      Aurora Cannabis (ACB) announced it has made a big move into the U.S. market via its acquisition of Reliva, LLC, one of the major players in America.The company said the at close the deal will be "immediately accretive to shareholders on an adjusted EBITDA basis."In this article we'll look at some of the strengths the two companies will complement each other with, and what means for the long-term prospects of Aurora.The dealThe two companies have agreed to have Aurora buy up "all of the issued and outstanding membership interests of Reliva."Per terms of the deal, Reliva members will receive about US$40 million of Aurora common shares. The members could receive up to US$45 million in earn-out in Aurora shares, cash, or a combination of the two, if Reliva reaches specific financial targets over the next two years.The deal is scheduled to close in June 2020, subject to normal closing conditions.This aligns nicely with Aurora's goal of reaching adjusted EBITDA profitability in the first fiscal quarter of 2021, with expectations the deal will be accretive to Aurora right away.Why it mattersAurora has been on a hot streak lately because of its surprising revenue beat in the last quarter, and while it was coming down to earth after the initial response from investors that drove its share price up, it has rebounded again on this positive news.What the deal adds to Aurora is it opens up the door to the U.S. hemp-derived CBD market. At this time Reliva sells its CBD brands in over 20,000 retail locations spread across the U.S.Also, as of March 2019, Reliva has generated positive EBITDA over the prior 12 months. Reliva is debt free as well. As of now, there is no need to provide working capital or any additional capital expenditures to Reliva. That also aligns well with the company's strategy of lowering costs and expenditures going forward.The company also gets packaged goods veteran Miguel Martin, who was named president of Aurora USA.Last but not least, Reliva has a solid record of successfully navigating the regulatory waters of the U.S. CBD market, and has been able to produce products and brands that are compliant with required standards.Leveraging the potentialReliva is the top ranked U.S. company in topicals, and is second in total market share in the U.S., according to IRI. Along with its 20,000-plus locations in the U.S. market, it also sells direct through its e-commerce platform.While that potential is obvious, where it really stands out is in the international presence of Aurora, where it has the largest footprint of all the cannabis producers in the world. Being able to leverage Reliva's CBD products across those various markets should quickly boost international sales, adding to the significant revenue Revila will bring in through existing sales.My view is that the criticism over Aurora's seemingly slow move into the U.S. market was excessive, as I've written a number of times, the company knew this was a huge decision, and now that we know the positive impact it'll have on the performance of Aurora, it's readily apparent the time it took to research and secure the deal warranted the time it took to do so. Almost everything associated with the deal aligns with the strategy being deployed by Aurora to generate long-term revenue and earnings.Combining the U.S. distributorship network of Reliva with the international distributorship network of Aurora, is a potent combination that is going to be difficult to compete against once it ramps up.ConclusionIt has been a while since positive sentiment has been associated with Aurora Cannabis, but with the results of its recent earnings report and the latest acquisition of U.S. CBD giant Reliva, it's clear Aurora has turned the corner and has little to stop it from sustainable growth going forward.That said, it still needs to be understood that some of the segments Aurora competes in will experience incremental growth. Even so, the inclusion of Reliva in its results in the second half of calendar 2020 and calendar full-year 2021 is going to result in a much different, and improved performance for the cannabis giant.Bottom line is Aurora Cannabis made a great acquisition here, and it will quickly improve its numbers in the near and long term.To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Read more: * 3 “Strong Buy” Penny Stocks That Could See Outsized Gains * 7 “Perfect 10” Stocks to Buy Now * Solid Insider Buying Puts These 3 Stocks in Focus

    • Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

      Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

      Welcome to the Cannabis Countdown. In This Week's Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of May 18th - 24th, 2020.Without further ado, let's get started.* Yahoo Finance readers, please click here to view full article.10\. FULLY UPDATED - These 2 Companies Could Be Turning LSD, Magic Mushrooms, Ketamine and MDMA into the Next Blockbuster DrugsInvestors Who Missed the Last Bull Market in Weed Stocks or Got in Too Late Should Start Researching the "Shroom Boom" ImmediatelyEarly cannabis investors and business minds are positioning themselves in the world of Psychedelic Medicine as the flow of smart money hits the market. Canopy Growth (NYSE: CGC) founder Bruce Linton and Billionaire "Mr. Wonderful" Kevin O'Leary from Shark Tank, are going all-in on what they think is a much bigger opportunity than the Cannabis Boom.Backed by popular demand, we have fully updated this article, which we originally published on 03/28/2020 to reflect the many significant developments that have occurred in the Psychedelics space over the past two months. Within a matter of hours, after the original version was released, it quickly went viral becoming our most viewed article off all-time within two days. Because the article is still experiencing very high traffic, we felt it was necessary to fully update it so our readers could have access to the most up to date information possible. In our opinion, the newly updated version is even better than the original so we highly suggest giving it a read if you're interested in learning about Psychedelic Medicine and the top investment opportunities in the sector.READ FULL SHROOM BOOM ARTICLE9\. Cannabis Boom 2.0: Here's Why 'Some Pot Stocks' Are Soaring Like We Haven't Seen Since 2018While the 1.5 Year Cannabis Correction Tested the Nerve of Investors, it Also Exposed the Weak Companies and Similar to the Dot-Com Bubble, Separated the Winners from the LosersCannabis Stocks are back in vogue following a lengthy bear market, which began at the same time Canada legalized adult-use marijuana in October 2018. With many of the losers of the 'Canadian Cannabis Bubble' now gone or close to it, the field has been narrowed down creating a more attractive environment for the winners to flourish and their share prices to continue rising. Check out our full list of winners and losers from the Cannabis Boom 1.0. This list of Pot Stocks will help investors focus their attention on the companies with the highest chance to succeed during the new Cannabis Boom 2.0, which is taking place in the world's largest marijuana market.READ FULL CANNABIS BOOM 2.0 ARTICLE8\. Psychedelic Stocks May Be One of the Most Undervalued Opportunities, Here's How to Play the Thriving New SectorSurging Investor Demand Continues to Be Concentrated into a Limited Number of Psychedelic StocksAs the Psychedelics industry continues to blossom, the current circumstances have created a situation for investors that has enormous potential upside. As more companies attempt to enter the burgeoning space, investors would be wise to focus their investment dollars on the proven sector leaders such as Champignon Brands (OTCQB: SHRMF) and MindMed (OTCQB: MMEDF).READ FULL PSYCHEDELIC STOCKS ARTICLE7\. These 2 Pot Stocks Have the Most Cash to Weather the DownturnCanopy and Cronos Have More Cash on Hand Than Most Other Cannabis Companies, But Are They Buys?Many marijuana companies have little by way of cash on hand to fund their operations, and many of them will have to take on additional debt -- or find ways to reduce their expenses -- to survive. Fortunately, some pot companies have a boatload of cash on their balance sheets. Let's look at two of these companies: Canopy Growth (NYSE: CGC) and Cronos Group (NASDAQ: CRON).READ FULL CANNABIS CASH ARTICLE6\. It's Time to Revisit Psychedelic Drugs That Are Proving Useful for HealthPsychedelic Drugs May Be Banned Around the World at the Moment, But That May Not Be the Case for Much LongerAs we learn more about how useful such treatments can be, it's opening a wide range of opportunities for the proven industry leaders like Champignon Brands (OTCQB: SHRMF) and Mind medicine MindMed (OTC: MMEDF). We're now seeing a wide range of other companies like The Yield Growth Corp. (CSE: BOSS), NewLeaf Brands (CSE: NLB), Pharmadrug Inc. (CSE: BUZZ), Numinus Wellness Inc. (TSXV: NUMI) enter the potential lucrative psychedelics space looking for a piece of the action.READ FULL PSYCHEDELIC MEDICINE ARTICLE5\. Cronos Group Can "Dominate" the American CBD Market: Raymond JamesDespite Ongoing Murkiness in the U.S. CBD Market Stocks Like Cronos Should Get a Boost From Aurora Cannabis' Recent Breakthrough CBD DealThat's according to analyst Rahul Sarugaser from Raymond James who reviewed the current state of affairs in a recent update to clients where he reiterated his "Market Perform 3" rating for Cronos Group (NASDAQ: CRON). Aurora Cannabis (NYSE: ACB) made a splash this week with the purchase of U.S. CBD company Reliva.READ FULL CRONOS GROUP ARTICLE4\. Champignon Brands Sponsors Group Focused on Medical Psilocybin Access Aimed at Palliative Cancer PatientsThe TheraPsil Coalition Will Start in 2020 Seeking Legal Access to Psilocybin for British Columbians With a Palliative Diagnosis and Psychological DistressChampignon Brands (CSE: SHRM) announced they have sponsored TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders seeking legal access to psilocybin for British Columbians with a palliative diagnosis and psychological distressREAD FULL CHAMPIGNON BRANDS ARTICLE3\. Trulieve Hits Milestone, Opens 50th -- And Largest -- U.S. DispensaryAccording to Trulieve, the Newly Opened Dispensary is Located in Daytona Beach, Bringing the Company's Total Stores in Florida to 48Trulieve (OTCQX: TCNNF) has cut the ribbon on its latest store, marking its 50th retail location. Located at 812 West International Speedway Boulevard, Trulieve's newest location is one of the company's largest. It spans about 6,000 square feet, and includes about 1,500 square feet of showroom space and 14 selling points.READ FULL TRULIEVE ARTICLE2\. Aurora Cannabis to Enter U.S. Market with Million of Acquisition of CBD Brand RelivaAurora Says it's Entering the U.S. Market by Acquiring Hemp-Based Cannabidiol Company RelivaAurora Cannabis (NYSE: ACB) will acquire all of the issued and outstanding membership interests of Reliva, while Reliva members will receive roughly US$40 million in Aurora's common shares.READ FULL AURORA CANNABIS ARTICLE1\. 3 Stocks to Buy for Psychedelic ProfitsBuy These Psychedelic Stocks to Get in on an Increasingly Popular Trend in HealthcarePsychedelic research is clearly gaining traction, and investors should take note. Here are three top Psychedelic Stocks to buy now: 1. Champignon Brands (OTCQB: SHRMF) 2. MindMed (OTCQB: MMEDF) 3. Revive Therapeutics (OTCPK: RVVTF)READ FULL PSYCHEDELIC STOCKS ARTICLEPhoto by Roberto Valdivia on UnsplashSee more from Benzinga * Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week * Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week * Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week(C) 2020 Benzinga does not provide investment advice. All rights reserved.

    • Aurora Cannabis' Exeter Sale Confirms the Need for Industrywide Writedowns
      Motley Fool

      Aurora Cannabis' Exeter Sale Confirms the Need for Industrywide Writedowns

      Most Canadian licensed producers are likely sitting on underutilized or unused assets that they won't be able to move.

    • High Tide to Open Canna Cabana Storefront in Burlington
      CNW Group

      High Tide to Open Canna Cabana Storefront in Burlington

      CALGARY , May 25, 2020 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of cannabis lifestyle accessories, is pleased to announce that the Canna Cabana retail cannabis store located in Unit #2 at 2400 Guelph Line in Burlington, Ontario (the "Burlington Store") will be opening on Wednesday, May 27, 2020 . It marks the sixth branded Canna Cabana location in Ontario and the Company's 35th retail cannabis store across Canada .

    • Tilray's CEO Expects at Least a Dozen Cannabis Bankruptcies in 2020 -- Is He Right?
      Motley Fool

      Tilray's CEO Expects at Least a Dozen Cannabis Bankruptcies in 2020 -- Is He Right?

      Canadian cannabis company Tilray's (NASDAQ: TLRY) CEO believes that at least 12 marijuana companies will go under this year. In March, Tilray announced that it would be raising $90.4 million through an offering, largely because the company still could. CEO Brendan Kennedy told BNN Bloomberg that he "wasn't sure anyone was going to be able to raise any money in this industry again" and that "when we had the opportunity to strengthen the balance sheet, we did."

    • Inside the Aurora Cannabis move into the U.S. CBD market

      Inside the Aurora Cannabis move into the U.S. CBD market

      The courtship between Aurora Cannabis Inc. and Reliva began, as many such romances do, at a gathering of industry bigwigs and bankers. It was not quite love at first sight.

    • Better Marijuana Stock: Aurora Cannabis vs. Cronos Group
      Motley Fool

      Better Marijuana Stock: Aurora Cannabis vs. Cronos Group

      Aurora Cannabis (NYSE: ACB) stock has skyrocketed by a triple-digit percentage in recent days after the Canadian cannabis producer reported better-than-expected fiscal 2020 third-quarter results. You might think that after this huge gain, Aurora is outperforming rival Cronos Group (NASDAQ: CRON), which posted Q1 results earlier this month that were below expectations. Which of these two marijuana stocks is the better pick going forward?

    • Why Is Everyone Talking About Aurora Cannabis?
      Motley Fool

      Why Is Everyone Talking About Aurora Cannabis?

      As a result, many investors are increasingly looking for stability in a volatile stock market. One cannabis company that has been making a lot of noise over the past couple of weeks or so is none other than Aurora Cannabis (NYSE: ACB). Aurora posted a string of poor financial performances last year and earlier in 2020.

    • Could Aurora Cannabis Turn Its Q3 Success Into Long-Term Growth?
      Motley Fool

      Could Aurora Cannabis Turn Its Q3 Success Into Long-Term Growth?

      Aurora Cannabis's (NYSE: ACB) stock has been wildly fluctuating since the release of its better-than-expected Q3 earnings report May 14 in which the company acknowledged $53.8 million in sales. First, Aurora's stock had an unusually strong day, surging upwards of 70% on Monday. Aurora may soon try to frame its favorable Q3 earnings as a hard-fought success in a market environment where wins are hard to come by.

    • Canada Licensed Marijuana Sales Jumped 19% in March
      Motley Fool

      Canada Licensed Marijuana Sales Jumped 19% in March

      In Statistics Canada's latest monthly domestic retail sales update, the government's official numbers cruncher revealed that cannabis sales rose by 19% on a month-over-month basis in March to $181 million Canadian (US$130 million). Much of this, it has to be said, is likely due to "stocking up" behavior among cannabis consumers. March is when mandatory business shutdowns necessitated by the the SARS-CoV-2 coronavirus began in many locations, Canada included.

    • Why Aurora Cannabis Stock Dropped on Friday
      Motley Fool

      Why Aurora Cannabis Stock Dropped on Friday

      Shares of Aurora Cannabis (NYSE: ACB) sank 6.6% on Friday after analysts at Jefferies downgraded the popular marijuana stock. Jefferies lowered its rating on Aurora's stock from hold to underperform. The investment bank says the recent surge in Aurora's share price is too much, too fast.